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This article describes the emerging evidence of hormonal inﬂuence on epileptogenesis,
which is a process whereby a brain becomes progressively epileptic due to an initial
precipitating event of diverse origin such as brain injury, stroke, infection, or prolonged
seizures. The molecular mechanisms underlying the development of epilepsy are poorly
understood. Neuroinﬂammation and neurodegeneration appear to trigger epileptogenesis.
There is an intense search for drugs that truly prevent the development of epilepsy in
people at risk. Hormones play an important role in children and adults with epilepsy.
Corticosteroids, progesterone, estrogens, and neurosteroids have been shown to affect
seizure activity in animal models and in clinical studies. However, the impact of hormones
on epileptogenesis has not been investigated widely. There is emerging new evidence
that progesterone, neurosteroids, and endogenous hormones may play a role in regulating
the epileptogenesis. Corticosterone has excitatory effects and triggers epileptogenesis
in animal models. Progesterone has disease-modifying activity in epileptogenic models.
The antiepileptogenic effect of progesterone has been attributed to its conversion to
neurosteroids, which binds to GABA-A receptors and enhances phasic and tonic inhibition
in the brain. Neurosteroids are robust anticonvulsants. There is pilot evidence that
neurosteroids may have antiepileptogenic properties. Future studies may generate new
insight on the disease-modifying potential of hormonal agents and neurosteroids in
epileptogenesis.
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INTRODUCTION
Epilepsy, one of the most common serious neurological disorders,
is characterized by the unpredictable occurrence of seizures. A
seizure is an abnormal electrical discharge in the brain that causes
an alteration in consciousness, sensations, and behaviors. The
symptoms that occur depend on the parts of the brain affected
during the seizure. Common signs of seizures include staring,
unusual feelings, twitching, unconsciousness, and jerking in the
arms or legs. Epilepsy affects an estimated 3 million Americans
and about 65million people worldwide in a variety of ways (Jacobs
et al., 2009; Hesdorffer et al., 2013). About 150,000 new cases of
epilepsy are diagnosed in the United States annually (Hesdorffer
et al., 2013). Children and adults are the fastest−growing segments
of the population with new cases of epilepsy.
Epilepsy is a collective designation for a group of brain dis-
orders consisting of a complex spectrum of different seizure
types and syndromes. Epileptic seizures are classiﬁed into par-
tial (simple and complex partial seizures) and generalized seizures
(absence, tonic–clonic, myoclonic, and atonic seizures). Accu-
rate diagnosis of seizure type and epileptic syndrome is critical
for determining appropriate drug therapy and prognosis. The
International League Against Epilepsy (ILAE) provided a deﬁ-
nition of “seizure” and “epilepsy” (Fisher et al., 2005). A seizure
is deﬁned as “a transient occurrence of signs and/or symptoms
due to abnormal synchronous neuronal activity in the brain.”
Epilepsy is deﬁned as “a disorder of the brain characterized by an
enduring predisposition to generate epileptic seizures.” A single
seizure, therefore, does not constitute epilepsy. The diagnosis
of epilepsy requires the occurrence of recurrent (two or more)
epileptic seizures separated by at least 24 h, unprovoked by any
immediate identiﬁed cause. Antiepileptic drugs (AEDs) are the
mainstay for controlling seizures (Table 1). Current drug ther-
apy is symptomatic in that available drugs inhibit seizures, but
neither effective prophylaxis nor cure are available. The goal of
the therapy is to eliminate seizures without interfering with nor-
mal function (Glauser et al., 2006, 2013). Despite many advances
in epilepsy research, presently an estimated 30% of people with
epilepsy have “intractable seizures” that do not respond to even
the best available medication. There is renewed focus on the
pathophysiology of epileptogenesis, the process whereby a brain
becomes progressively epileptic due to an initial precipitating
event.
This article describes the emerging evidence of hormonal
inﬂuence on epileptogenesis and the potential mechanisms under-
lying their actions on neuronal excitability and seizure activity.
It also describes recent studies on neurosteroid agents that pre-
vent or delay the development of epilepsy. The main focus
of the review is on steroid hormones and neurosteroids with
seizure-modulating activity. Neuropeptides and other hormones
such as oxytocin, neuropeptide-Y, and galanin, which may affect
neuronal excitability, are not discussed here because such descrip-
tion is beyond the scope of this article. The seizure-modulating
effects of neuropeptides are discussed elsewhere (Robertson et al.,
2011).
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Table 1 | List of current antiepileptic drugs.
Standard (first generation) Newer (second generation)
Carbamazepine (Tegretol) Acetazolamide (Diamox)
Clonazepam (Klonopin) Clobazam (Onﬁ)
Chlorazepate (Tranxene) Ezogabine (Potiga)
Diazepam (Valium) Felbamate (Felbatol)
Divalproex sodium (Depakote) Fosphenytoin (Cerebyx)
Ethosuximide (Zarontin) Lacosamide (Vimpat)
Ethotoin (Peganone) Lamotrigine (Lamictal)
Lorazepam (Ativan) Levetiracetam (Keppra)
Mephobarbital (Mebaral) Oxcarbazepine (Trileptal)
Methsuximide (Celontin) Parampanel (Fycompa)
Nitrazepam (Mogadon) Pregabalin (Lyrica)
Phenobarbital (Gardinal) Progabide (Gabrene)
Phenytoin (Dilantin) Ruﬁnamide (Banzel)
Primidone (Mysoline) Tiagabine (Gabitril)
Valproic acid (Depakene) Topiramate (Topamax)
Vigabatrin (Sabril)
Zonisamide (Zonegran)
OVERVIEW OF EPILEPTOGENESIS AND INTERVENTION
STRATEGIES
Epilepsy is a chronic conditionwithmanypossible causes. Epilepsy
may develop because of an abnormality in neural connectivity,
an imbalance in inhibitory and excitatory neurotransmitters, or
some combination of these factors. Primary epilepsy (50%) is idio-
pathic (“unknown cause”). In secondary epilepsy (50%), seizures
may result from a variety of conditions including trauma, anoxia,
metabolic imbalances, tumors, encephalitis, drug withdrawal, and
neurotoxicity (Engel et al., 2007). The molecular mechanisms
underlying the development of acquired epilepsy are not very
well understood. The term “epileptogenesis” is used to describe
the complex plastic changes in the brain that, following a precip-
itating event, convert a normal brain into a brain debilitated by
recurrent seizures (Pitkänen et al., 2009; Pitkänen and Lukasiuk,
2011). Although speciﬁc types of epilepsy may have unique patho-
physiological mechanisms, a broad hypothesis in this ﬁeld is that
convergent neuronal mechanisms are common in different forms
of acquired epilepsy.
The current hypothesis about the pathogenesis of epilepsy
(epileptogenesis) involves three stages: (1) the initial precipi-
tating event; (2) the latent period (no seizures); and (3) the
chronic period with spontaneous seizures (Figure 1). Acquired
epilepsy typically develops due to an initial precipitating event
such as traumatic brain injury (TBI), stroke, brain infections, or
prolonged seizures. The other possible precipitating triggers for
epileptogenesis include febrile seizures, metabolic dysfunction,
alcohol withdrawal, and status epilepticus, an emergency con-
dition characterized by continuous seizures or repeated seizures
without regaining consciousness for 30 min or more (McClel-
land et al., 2011). Exposure to organophosphorous pesticides and
FIGURE 1 | Pathophysiology of epileptogenesis. Epileptogenesis is the
process whereby a normal brain becomes progressively epileptic because
of precipitating injury or risk factors such asTBI, stroke, brain infections, or
prolonged seizures. Epilepsy development can be described in three
stages: (1) the initial injury (epileptogenic event); (2) the latent period (silent
period with no seizure activity); and (3) chronic period with spontaneous
recurrent seizures. Although the precise mechanisms underlying spatial
and temporal events remain unclear, epileptogenesis may involve an
interaction of acute and delayed anatomic, molecular, and physiological
events that are both complex and multifaceted. The initial precipitating
factor activates diverse signaling events, such as inﬂammation, oxidation,
apoptosis, neurogenesis, and synaptic plasticity, which eventually lead to
structural and functional changes in neurons. These changes are eventually
manifested as abnormal hyperexcitability and spontaneous seizures.
chemical warfare nerve agents, such as soman, can cause epilepsy
as a result of cholinergic neurotoxicity and status epilepticus (de
Araujo Furtado et al., 2012).
The development of epileptogenesis is thought to be a step-
function of time after the brain injury, with a latent period
present between the brain injury and the ﬁrst unprovoked seizure.
There are some alternative hypotheses to this notion that view
epileptogenesis as a continuous process that extends past the
ﬁrst spontaneous seizure (Dudek and Staley, 2011). Temporal
lobe epilepsy (TLE) is one of the common forms of chronic
epilepsies (Wieser and ILAE Commission on Neurosurgery of
Epilepsy, 2004). TLE is characterized by the progressive expan-
sion of spontaneous seizures originating from the limbic system
regions, especially the hippocampus, most often due to neuronal
injury. The hippocampal sclerosis, which is characterized by aber-
rant mossy ﬁber sprouting and widespread neuronal loss in the
dentate hilus and CA1 and CA3 subﬁelds, is the hallmark of
epilepsy pathology (Sutula et al., 1989; Buckmaster et al., 2002;
Nadler, 2003; Morimoto et al., 2004). However, there is an ongo-
ing debate about whether the hippocampal sclerosis is the basis
or the outcome of recurring seizures. There is emerging evidence
from refractory models that epilepsy involves “progressive epilep-
togenesis” much beyond the latent period and the onset of the
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ﬁrst seizure (Williams et al., 2009). Several mechanisms have been
described including loss of interneurons (van Vliet et al., 2004;
Sloviter and Bumanglag, 2013) and neuroinﬂammation (Vezzani
et al., 2011). There is great variation in the onset of spontaneous
seizures following a precipitating factor (Rao et al., 2006; Norwood
et al., 2010). Thus, the critical window for effective “antiepilepto-
genic” interventions remain poorly deﬁned for curing epilepsy in
people at risk.
Studies in animal models have provided improved under-
standing of neurophysiological basis of epileptic seizures (O’Dell
et al., 2012; Simonato et al., 2012). Spontaneous seizures arise
from hyperexcitable and hypersynchronous neuronal networks
and involve both cortical and several key subcortical structures.
The general cellular pathway underlying occurrence of epileptic
seizures is apparent in three phases: (i) focal epileptogenicity (ini-
tiation); (ii) synchronization of the surrounding neurons (sync);
and (iii) propagation of the seizure discharge to other areas of
the brain (spread). Experimental ﬁeld and intracellular record-
ings in isolated brain sections provide a detailed description of
neurophysiological abnormalities underlying epileptic regions.
Paroxysmal depolarization shift (PDS) is identiﬁed as a hallmark
of epileptic neurons. It is characteristic of neurons in epileptic
cortical zones and consists of an abnormally prolonged depo-
larization with repetitive spiking reﬂected as interictal discharges
in the electroencephalogram (EEG). High-frequency oscillations,
termed ripples (80–200 Hz) and fast ripples (250–600 Hz), are
recorded in the EEG of epileptic patients and in animal epilepsy
models (Köhling and Staley, 2011; Lévesque et al., 2011). Fast rip-
ples are thought to reﬂect pathological activity and seizure onset
zones.
Gowers (1881) proposed that seizures beget seizures. The kin-
dling model has provided a conceptual framework for this idea
and for developing new molecular targets for preventing epilepsy
(Goddard et al., 1969; McNamara et al., 1992). Post-status epilep-
ticus paradigms are widely used for modeling the epileptogenesis
in which a single episode of prolonged seizures (by pilocarpine,
kainate, or electrical stimulation) triggers progressive develop-
ment of seizure activity (Buckmaster and Dudek, 1997; Hellier
et al., 1999; Glien et al., 2001; Rao et al.,2006; Löscher,2012). These
chronic models share many features of human limbic epilepsy
(Löscher, 2002; Stables et al., 2002). Pilocarpine, kainate, or per-
forant path stimulation induce acute SE and neuronal injury and
follow a pattern of latent period similar to that observed in limbic
epilepsy. Like TLE,mossy ﬁber sprouting, neurodegeneration, and
ectopic granule cell proliferation are evident after the latent period
(Löscher, 2002; Rao et al., 2006).
Despite decades of research, currently there is no single
Food and Drug Administration (FDA)-approved drug that truly
prevents the development of epilepsy in people at risk. A
variety of intervention approaches have been tested in ani-
mal models of epileptogenesis (Acharya et al., 2008; Pitkä-
nen and Lukasiuk, 2011). A number of clinical trials show a
lack of antiepileptogenic efﬁcacy of AEDs, including pheny-
toin and carbamazepine, in patients at high risk for developing
epilepsy (Temkin, 2001; Mani et al., 2011). There is a desperate
need for drugs that truly prevent the development of epilepsy
(“antiepileptogenic agents”) or alter its natural course to delay the
appearance or severity of epileptic seizures (“disease-modifying
agents”).
In 2000, National Institute of Neurological Disorders and
Stroke (NINDS) and epilepsy research and advocacy groups orga-
nized the ﬁrst “Curing Epilepsy” conference, which marked a
turning point for shifting and expanding the focus of epilepsy
research toward cures for epilepsy and the prevention of epilepsy
in those at risk (Jacobs et al., 2001). During the past decade,
there has been increasing research emphasis on the preven-
tion of epileptogenesis and translation of lead discoveries in
this ﬁeld into therapies for curing epilepsy (Jacobs et al., 2009;
Simonato et al., 2012). The Institute of Medicine (IOM) released
a consensus report in 2012 on public health dimensions of
the epilepsies focusing on promoting health and understand-
ing epilepsy (Austin et al., 2012; Hesdorffer et al., 2013). The
IOM report, Epilepsy Across the Spectrum: Promoting Health and
Understanding, provided 13 recommendations for future work
in the ﬁeld of epilepsy. The report contains research priori-
ties which include one key recommendation on prevention of
epilepsy.
ROLE OF STEROID HORMONES IN EPILEPTOGENESIS
Steroid hormones play a key role in the neuroendocrine con-
trol of neuronal excitability and seizure susceptibility (Table 2;
Herzog, 2002; Reddy, 2003a, 2010; Verrotti et al., 2007). Steroid
hormones are synthesized and secreted fromovarian, gonadal, and
adrenal sources. In men, the main circulating steroids are andro-
genic steroids (testosterone and dihydrotestosterone) and adrenal
corticosteroids (cortisol and aldosterone). Deoxycorticosterone
(DOC) is also released from adrenal cortex in response to stress.
In women, the primary reproductive steroid hormones are estro-
gens and progesterone, which are released during the menstrual
cycle. The early follicular phase is associated with low levels of
estrogens and progesterone. The synthesis and secretion of estro-
gens and progesterone from the ovaries are controlled primarily by
hypothalamic gonadotropin releasing hormone (GnRH) and the
pituitary gonadotropins, follicle stimulating hormone (FSH) and
luteinizing hormone (LH). As ovulation approaches, the level of
estrogen rises and triggers a large surge of LH leading to ovulation.
Table 2 | List of steroid hormones and neurosteroids that affect seizure
susceptibility.
Anticonvulsant steroids Proconvulsant steroids
Progesterone Estradiol
Allopregnanolone Pregnenolone sulfate
Pregnanolone DHEA sulfate
Dihydroprogesterone Cortisol
Androstanediol 11-Deoxycortisol
Etiocholanone
Dihydrotestosterone
Deoxycorticosterone
Dihydrodeoxycorticosterone
Allotetrahydrodeoxycorticosterone
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Following ovulation, the ruptured follicle luteinizes and forms a
corpus luteum that secretes progesterone and estrogen. Estradiol
is secreted in the second half of the follicular phase and increases
to a peak at midcycle, while progesterone is elevated during the
luteal phase and declines before menstruation begins.
The cyclical changes of estrogens and progesterone are now
widely believed to be important in the pathogenesis of catame-
nial epilepsy, a menstrual cycle-related seizure disorder in women
with epilepsy (Reddy, 2009a, 2013). Catamenial epilepsy is a mul-
tifaceted neuroendocrine condition in which seizures are clustered
around speciﬁc points in the menstrual cycle, most often around
perimenstrual or periovulatory period. Generally, estrogens are
found to be excitatory or proconvulsant, while progesterone has
powerful antiseizure effect and reduces seizures, and thus they play
a central role in the pathophysiology of epilepsy in women (Reddy,
2009a, 2013). Progesterone is an intermediate precursor for the
synthesis of neurosteroids, which are increased in parallel during
the ovarian cycle. There is emerging evidence that endogenous
neurosteroids inﬂuence seizure susceptibility and epileptogenesis
(Reddy, 2011; Reddy and Rogawski, 2012).
PROGESTERONE
Progesterone is an endogenous anticonvulsant hormone with sub-
stantial impact on seizure susceptibility. The potential molecular
pathways for the progesterone modulation of seizure activity are
illustrated in Figure 2. Progesterone is an appealing hormone for
prophylactic interventions on epilepsy development, due to its
multifunctional modulatory actions in the brain. Progesterone
has long been known to have antiseizure activity in animal models
(Selye, 1942; Craig, 1966; Kokate et al., 1999a; Frye and Scalise,
2000; Reddy et al., 2004), and in clinical studies (Bäckström et al.,
1984; Herzog, 1995, 1999). Women with epilepsy are prone to
FIGURE 2 | Biosynthesis and targets of steroid hormones and
neurosteroids in the brain. Enzymatic pathways for the production of
three prototype neurosteroids allopregnanolone, THDOC, and androstanediol
are illustrated from cholesterol. Steroid hormones progesterone,
deoxycorticosterone, and testosterone undergo two sequential A-ring
reduction steps catalyzed by 5α-reductase and 3α-HSOR to form the
5α,3α-reduced neurosteroids. The conversion of intermediate precursor
steroids into neurosteroids occurs in the hippocampus and several other
regions within the brain, where they can affect neuronal function. As evident
from the pathways, many modiﬁcations are made by the same enzymes,
which can be blocked by speciﬁc inhibitors (trilostane, ﬁnasteride, and
indomethacin). There are two mechanisms by which steroid hormones affects
neuronal function: (i) binding to steroid receptors (PRs, ARs, or MRs; left
panel) and (ii) conversion to GABA-A receptor-modulating neurosteroids (right
panel). Progesterone, deoxycorticosterone, or testosterone binding to their
cognate steroid receptors could lead to activation of gene expression in the
brain. Neurosteroids rapidly modulate neuronal excitability by direct
interaction with inhibitory GABA-A receptors in the brain.
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seizures in response to decreased levels of progesterone during
perimenstrual periods (Herzog et al., 1997; Reddy, 2009a). Indeed,
the incidence of epilepsy is generally lower in women than in men
(Hauser et al., 1993; Christensen et al., 2005;McHugh andDelanty,
2008). This gender difference could be caused by ovarian hor-
mones such as progesterone. Although progesterone is known to
inhibit stimulation-evoked seizures in kindling models (Holmes
andWeber, 1984; Mohammad et al., 1998; Lonsdale and Burnham,
2003), it has not been investigated widely for potential disease-
modifying effect in epileptogenic models. In the kindling model,
progesterone has been shown to impair or retard epileptogenesis
(Holmes andWeber, 1984; Edwards et al., 2001; Reddy et al., 2010).
Recently progesterone has been evaluated in an National Insti-
tutes of Health (NIH)-sponsored, multicenter clinical trial as
a treatment for epilepsy in women (Herzog et al., 2012). This
randomized, double-blind, placebo-controlled, phase III, multi-
center, clinical trial compared the efﬁcacy and safety of adjunctive
cyclic natural progesterone therapy versus placebo treatment of
intractable seizures in 294 subjects randomized 2:1 to proges-
terone or placebo, stratiﬁed by catamenial and non-catamenial
status. The results indicate lack of signiﬁcant difference in propor-
tions of responders between progesterone and placebo groups.
However, a more restricted analysis on a subset of the data
found a signiﬁcantly higher responder rate in women with per-
imenstrual seizure exacerbation. These ﬁndings suggest that
progesterone may provide a clinically important beneﬁt for a
subset of womenwith perimenstrual catamenial epilepsy. The dra-
matic response to progesterone, which is a neurosteroid precursor,
in women with perimenstrual catamenial epilepsy is attributable
to the unique neurosteroid sensitivity of perimenstrual catamenial
seizures (Reddy, 2009a).
Previous studies have shown that progesterone supports the
normal development of neurons, and that it reduces the extent
of brain damage after TBI (Roof et al., 1994; Cutler et al., 2005,
2007; Stein, 2013). It has been observed in animal models that
females have reduced susceptibility toTBI and this protective effect
has been hypothesized to be caused by increased circulating lev-
els of progesterone in females (Roof and Hall, 2000; Meffre et al.,
2007). A number of additional studies have conﬁrmed that proges-
terone has neuroprotective effects (Gibson et al., 2008; Singh and
Su, 2013). Promising results have also been reported in human
clinical trials. Recently, two clinical studies have evaluated proges-
terone as a treatment for moderate to severe TBI (Wright et al.,
2007; Xiao et al., 2008). These studies demonstrated the efﬁcacy
of progesterone as a neuroprotective agent in TBI. Progesterone is
highly efﬁcacious in reducing disability and death in TBI. Proges-
terone has neuroprotective properties in acute models of ischemic
injury, stroke, and astroglial dysfunction (Koenig et al., 1995; Jiang
et al., 1996; He et al., 2004), suggesting its beneﬁcial effects in brain
injury.
Progesterone targets multiple molecular and cellular mecha-
nisms relevant to epileptogenesis, and may therefore be a natural
disease-modifying agent. Progesterone’s cellular actions are medi-
ated by the progesterone receptors (PRs), which are expressed
in the hypothalamus, neocortex, hippocampus, and limbic areas
(Brinton et al., 2008). Progesterone is an intermediate precursor
for the synthesis of neurosteroids (see Role of Neurosteroids in
Epileptogenesis). Progesterone’s antiseizure activity is mediated
mainly by its conversion to allopregnanolone, a neurosteroid and
positive modulator of GABA-A receptors with broad-spectrum
antiseizure properties (Belelli et al., 1989; Kokate et al., 1999a; Frye
et al., 2002; Kaminski et al., 2004; Reddy et al., 2004). Moreover,
neurosteroids can modulate PRs via intracellular metabolism to
analogs that bind to PRs (Rupprecht et al., 1993). Progesterone
maymodulate signaling cascades of inﬂammation, apoptosis, neu-
rogenesis, and synaptic plasticity (Patel, 2004; Vezzani, 2005; Stein
and Sayeed, 2010), and therefore, progesterone may directly exert
disease-modifying effects on epileptogenesis.
Recently, progesterone has been tested in rodent models of
hippocampus epileptogenesis (Reddy et al., 2010; Reddy and
Mohan, 2011; Reddy and Ramanathan, 2012). At low, non-
sedative doses, progesterone treatment for 2 weeks signiﬁcantly
suppressed the rate of development of kindled seizure activity
evoked by daily hippocampus stimulation in mice, indicating a
disease-modifying effect of progesterone on limbic epileptoge-
nesis. There was a signiﬁcant increase in the rate of “rebound
or withdrawal” kindling during drug-free stimulation sessions
following abrupt discontinuation of progesterone treatment. A
washout period after termination of progesterone treatment pre-
vented such acceleration in kindling. The molecular mechanisms
underlying progesterone’s attenuating effect on kindling develop-
ment remains unknown. There are several potential mechanisms
by which progesterone could inhibit epileptogenesis, including
activation of PRs, synthesis of neurosteroids, modulation of
oxidative cascades, and promoting neuroprotection. The effect
of progesterone on the early kindling progression is reduced in
mice lacking PRs, which provide evidence that PRs may be partly
involved in progesterone’s disease-modifying effects (Reddy et al.,
2010). These ﬁndings are consistent with the role of PRs in pro-
gesterone inhibition of epileptiform activity in the hippocampus
(Edwards et al., 2000). Despite the early attenuation, late stage
kindling progressed normally in the PRKO mice, suggesting that
PRs are not involved in the later part of the kindling progres-
sion. However, the extent to which PRs mediate the progesterone’s
disease-modifying effect remains unclear. Collectively, the disease-
modifying effect of progesterone may occur through a complex
mechanism partly involving PR-dependent and PR-independent
pathways.
Progesterone is rapidly metabolized into neurosteroids preg-
nanolone and allopregnanolone, which could mediate proges-
terone’s attenuating effects on kindling epileptogenesis. This
possibility is supported by emerging evidence that neurosteroids
can retard the development of spontaneous seizures in post-
SE models of epileptogenesis (Biagini et al., 2006, 2009). It is
suggested that 5α-reductase converts progesterone to allopreg-
nanolone and related neurosteroids that retard epileptogenesis.
To further test this hypothesis, we utilized the mouse hippocam-
pus kindling model of epileptogenesis and investigated the effect
of ﬁnasteride, a 5α-reductase and neurosteroid synthesis inhibitor
(Reddy andRamanathan,2012). In a kindlingmodel in adultmice,
pre-treatmentwith ﬁnasteride signiﬁcantly blocked progesterone’s
inhibition of epileptogenesis (Reddy and Mohan, 2011), and led
to complete inhibition of the progesterone-induced retardation of
limbic epileptogenesis in mice (Reddy and Ramanathan, 2012).
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Therefore, neurosteroids such as allopregnanolone may mediate
the disease-modifying effect of progesterone in the kindlingmodel
(see Role of Neurosteroids in Epileptogenesis).
In addition, progesterone’s modulation of inﬂammation is
suggested as an appealing mechanism because pro-inﬂammatory
molecules and oxidative signaling has been found to be acti-
vated in animal models of epilepsy (Patel, 2004; Vezzani, 2005).
Progesterone has pleiotropic effects on inﬂammation and cell
growth/survival (He et al., 2004; Stein and Sayeed, 2010) that may
contribute to its attenuating effects on epileptogenesis. Proges-
terone inhibits secreted phospholipase A2 enzyme, a very high
level target in the inﬂammatory cascade that has been shown to
induce neurodegeneration through glutamate release (DeCoster
et al., 2002; Yagami et al., 2002). Progesterone has been shown in
numerous preclinical models to be neuroprotective after injury
(Roof et al., 1994; Koenig et al., 1995; Jiang et al., 1996; Cutler
et al., 2007). Recently, two clinical studies have evaluated proges-
terone as a treatment for moderate to severe TBI (Wright et al.,
2007; Xiao et al., 2008). The progesterone was administered over a
period of 3 or 5 days beginning within 8 or 11 h of the injury. In
both studies, the groups receiving progesterone had signiﬁcantly
fewer deaths than those receiving placebo. In addition, there was
evidence of improved functional outcomes in the progesterone-
treated groups, suggesting that progesterone is highly efﬁcacious
in reducing morbidity and mortality in TBI, which is a leading
cause of epilepsy in adults and military persons.
TESTOSTERONE
Testosterone has marked impact on seizure susceptibility. The
potential biosynthetic pathways of testosterone metabolism are
illustrated in Figure 2. Testosterone is known to produce both
proconvulsant and anticonvulsant effects depending on the ani-
mal model and the seizure type (Reddy, 2008). Both animal and
clinical studies show that testosterone enhances seizure activity
by metabolism to estrogens (Isojarvi et al., 1988; Thomas and
Yang, 1991; Herzog et al., 1998; Edwards et al., 1999; El-Khayat
et al., 2003). Epidemiological data indicate that the occurrence of
focal and tonic–clonic epileptic seizures is ∼50% higher in intact
than in castrated dogs (VMDB Report, 2003). On the contrary,
testosterone and related androgens have protective effects against
seizures induced by pentylenetetrazol and kainic acid (Schwartz-
Giblin et al., 1989; Frye and Reed, 1998; Frye et al., 2001a,b;
Reddy, 2004b). Moreover, studies in orchidectomized or cas-
trated animals have shown that decreased testosterone is associated
with higher incidence of seizures and replacement with testos-
terone attenuates seizures (Grigorian and Khudaverkian, 1970;
Thomas and McLean, 1991; Pericic´ et al., 1996; Pesce et al., 2000).
It is demonstrated that testosterone modulation of seizure sus-
ceptibility occurs through its conversion to neurosteroids with
“anticonvulsant” and “proconvulsant” actions, and hence the net
effect of testosterone on neural excitability and seizure activity
depends on the levels of distinct testosterone metabolites within
the brain (Reddy, 2004a,b). Unlike estradiol, which generally facil-
itates seizures (Bäckström, 1976; Hom and Buterbaugh, 1986;
Buterbaugh, 1989;Woolley, 2000), androstanediol has been shown
to produce powerful antiseizure effects (Reddy, 2004b; Kaminski
et al., 2005). Testosterone might have a biphasic effect on seizures:
proconvulsant at higher doses, anticonvulsant at lower doses.
However, testosterone itself has not been reported to improve
seizures clinically (Herzog et al., 1998). Reductions of seizures
were observed only when testosterone was given together with
an estrogen synthesis inhibitor (Herzog et al., 1998), suggesting
the estradiol modulation of seizure activity.
Inmanymenwith epilepsy, testosterone deﬁciency is an unusu-
ally common clinical observation (Macphee et al., 1988; Herzog,
1991; El-Khayat et al., 2003). TLE surgery has been shown to
reduce seizure occurrence and normalize serum androgen con-
centrations in men with epilepsy (Bauer et al., 2000). Alterations
in testosterone levels, therefore, may possibly contribute to exac-
erbation of seizures. The introduction of ﬁnasteride (Propecia),
which inhibits dihydrotestosterone and androstanediol synthe-
sis, for the treatment of male pattern baldness led to recurrent
seizures, which then subsided once the drug was discontinued.
Finasteride-induced seizure exacerbation has also been reported
recently (Herzog and Frye, 2003). There is a new case report impli-
cating endogenous neurosteroids in TLE (Pugnaghi et al., 2013).
Two-week phenytoin treatment has been shown to affect the hip-
pocampal levels of testosterone, cytochromeP450 (CYP) isoforms,
and androgen receptor (AR) expression (Meyer et al., 2006). The
increasedmetabolismof testosterone leading to augmented andro-
gen metabolite formation most likely led to enhanced expression
of CYP19 and AR in hippocampus, which is a critical area for
limbic epileptogenesis.
Aromatase is the key enzyme for the conversion of testos-
terone to estradiol, a neuroactive steroid that promotes seizures.
Aromatase is expressed in discrete areas in the brain such as hip-
pocampus and neocortex that are involved in epileptogenesis.
Aromatase inhibitors could decrease brain excitability by decreas-
ing local estradiol levels and therefore, could be beneﬁcial for
the treatment of epilepsy (MacLusky et al., 1994). Consequently,
aromatase inhibitors have been proposed as a suitable approach
to seizure therapy in some men with epilepsy. Some aromatase
inhibitors have been tested in men with epilepsy: testolactone,
letrozole, and anastrozole. Herzog et al. (1998) tested the efﬁcacy
of testosterone and testolactone in men with intractable complex
partial seizures. Improvement in seizure control was reportedly
achieved with testosterone therapy when testosterone was used
along with testolactone. In a case report, letrozole has been shown
to improve seizure control in a 61-year-old man with epilepsy
(Harden and MacLusky, 2004, 2005). In a pilot study, the safety
and efﬁcacy of add-on anastrozole therapy was tested in men
with intractable epilepsy. Men with the greatest seizure reduction
showed unexpectedly elevated levels in FSH, a pituitary-derived
gonadotropin. Hence, the outcome of trials with three distinct
aromatase inhibitors – testolactone, letrozole, and anastrozole –
suggests a beneﬁcial treatment modality for men with epilepsy
(Harden and MacLusky, 2005). Therefore, it is likely that aro-
matase inhibitors could be potential agents for interruption of
proepileptogenic estrogens in the brain.
ESTROGENS
Although estrogens can affect seizure susceptibility, the role of
various estrogens in epileptogenesis is poorly understood. In gen-
eral, estrogens have proconvulsant and epileptogenic properties
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in animals and humans (Scharfman and MacLusky, 2006). There
are limited studies that support protective effects of estrogens, but
it may act as a anticonvulsant under some conditions (Velíšková,
2006). Estradiol has been widely investigated in animal epilepsy
models. The effect of estrogens on seizure susceptibility is highly
variable and depends on factors such as treatment duration,
dosage, hormonal status, and the seizure model (Velíšková and
Velísek, 2007). Early studies of estradiol administration to ovariec-
tomized rats revealed proconvulsant effects (Reddy, 2009a). The
effect of estrogens onhippocampus seizure susceptibility is contro-
versial (Scharfman and MacLusky, 2006). While estradiol has been
shown to be proconvulsant in several studies, there is also evidence
that support lack of effect or protective effect of estrogens (Reibel
et al., 2000; Velíšková et al., 2000; Velíšková andVelísek, 2007). The
effect of circulating estrogens has been studied in female rats with
epilepsy (Scharfman et al., 2008, 2009). Epileptic female rats show
cyclic increases in epileptiform activity in EEG recordings that
coincide with their ovarian cycle, mostly attributable to estrogens.
Estradiol has been known to play a role in the exacerba-
tion of seizures in women with epilepsy (Logothetis et al., 1959;
Bäckström, 1976; Jacono and Robinson, 1987). Plasma estra-
diol levels are found to increase during both the follicular and
luteal phase of the normal menstrual cycle. Bäckström (1976)
was the ﬁrst investigator to characterize the relationship between
seizures and steroid hormones. In women with epilepsy, a positive
correlation between seizure susceptibility and the estrogen-to-
progesterone ratio was observed, peaking in the premenstrual and
preovulatory periods and declining during the midluteal phase.
Logothetis et al. (1959) have demonstrated that intravenous infu-
sions of estrogen were associated with rapid interictal epileptiform
activity in women with epilepsy, and seizures were exacerbated
when estrogen was given premenstrually. Therefore, it is hypoth-
esized that estrogens may facilitate some forms of catamenial
seizures observed during these phases. The periovulatory cata-
menial exacerbation has been attributed to the midcycle surge of
estrogen that is relatively unopposed by progesterone until early
luteal phase (Logothetis et al., 1959). An increase in the ratio
of estrogen-to-progesterone levels during perimenstrual period
might at least partly contribute to the development of peri-
menstrual catamenial epilepsy (Bonuccelli et al., 1989; Herzog
et al., 1997). A recent report from the Nurses’ health study in
114,847 nurses identiﬁed key factors associated with seizures in
women with epilepsy (Dworetzky et al., 2012). Menstrual irreg-
ularity at ages 18–22 years was speciﬁcally associated with an
increased risk of epilepsy. Menstrual irregularity during follow-up
and early age at menarche increased the risk of isolated seizures.
Oral contraceptive uses are not associated with isolated seizure or
epilepsy.
GLUCOCORTICOIDS
Pituitary–adrenal hormones have long been known to affect
epileptogenesis (Aird and Gordan, 1951; Rose et al., 1979; Weiss
et al., 1993; Joëls, 2009; Borekci et al., 2010). Acute stress raises
seizure threshold in animals, but chronic stress is known to
be a clear risk factor for precipitating seizures in patients with
epilepsies. Stress increases plasma and brain concentrations of
corticosteroids and neurosteroids. Acute physical or psychological
stress causes increased production of hypothalamic corticotrophin
releasing hormone (CRH), which is transported via hypophyseal
portal system to the pituitary, where it increases both adreno-
corticotropic hormone (ACTH) synthesis and secretion. Major
physiological effects result from ACTH’s action on adrenal cor-
tex to increase the circulating levels of corticosteroids, principally
the glucocorticoid cortisol, and the mineralocorticoid DOC. Cor-
tisol is a major corticosteroid secreted from the adrenal cortex.
Cortisol is an excitatory steroid. It elicits proconvulsant and epilep-
togenic effects (Roberts and Keith, 1995; Joëls, 1997). DOC elicits
inhibitory effects and protects against seizures (Reddy, 2003b).
An imbalance in cortisol and DOC and other corticosteroids may
contribute to susceptibility or resistance to epileptogenesis.
Stress enhances epileptogenesis. In general, chronic or repeated
stress has been shown to enhance vulnerability to epileptogen-
esis in animal models (Joëls, 2009). Corticosterone, the major
adrenal steroid in rodents, has been tested extensively in animal
models (Weiss et al., 1993; Kumar et al., 2007, 2011; Joëls, 2009;
Borekci et al., 2010; Desgent et al., 2012). Prolonged exposure to
elevated corticosterone, used as a model of chronic stress, accel-
erates limbic epileptogenesis (Kumar et al., 2007). Exposure to
repeated experimental stress accelerates the development of lim-
bic epileptogenesis, an effect which may be related to elevated
corticosterone levels (Jones et al., 2013). Chronic low-dose corti-
costerone supplementation is shown to enhance epileptogenesis
in the rat amygdala kindling model (Kumar et al., 2007). Episodic
corticosterone treatment elicits a striking acceleration in kindling
epileptogenesis and triggers long-term changes in hippocampal
CA1 neurons (Karst et al., 1999). Overall, corticosterone – with
other stress hormones – rapidly enhances CA1/CA3 hippocam-
pal activity shortly after stress and could imposes a risk for
neuronal injury, such as during epileptic activity. In the hippocam-
pus, stress-induced elevations inneurosteroids promote inhibitory
tone mediated through GABA-A receptors. Under conditions of
repetitive stress, hormonal inﬂuences on the inhibitory tonemight
diminish and instead, increased excitation become more apparent.
In agreement, perinatal stress and elevated corticosteroid levels
accelerate epileptogenesis and lower seizure threshold in rodent
epilepsy models (Salzberg et al., 2007; Lai et al., 2009; Desgent
et al., 2012). Therefore, exposure to stressful events during a criti-
cal phase in epileptogenesis could impose lastingdeleterious effects
on the course of epilepsy.
Deoxycorticosterone, a mineralocorticoid precursor with anes-
thetic and antiseizure properties, is also produced in the adrenal
zona fasciculate. Although the antiseizure properties of DOC
in human were ﬁrst described in 1944 (Aird, 1944; Aird and
Gordan, 1951), the mechanisms underlying the brain actions
of DOC were only recently identiﬁed. The antiseizure activity
of DOC requires its enzymatic conversion to 3α,21-dihydroxy-
5α-pregnan-20-one (THDOC), a neurosteroid that is a powerful
positive allosteric modulator of GABA-A receptors (Reddy, 2003b;
Figure 2). THDOC is released during physiological stress nearly
exclusively fromadrenal sources (Purdy et al., 1990; Reddy,2003b).
Plasma and brain levels of THDOC rise rapidly following acute
stress (Purdy et al., 1991; Concas et al., 1998; Reddy and Rogawski,
2002). Acute stressors such as swimming, foot shock, or car-
bon dioxide exposure elicit an increase in allopregnanolone and
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THDOC concentrations in plasma and in brain (Barbaccia et al.,
1996, 1997; Vallée et al., 2000). Stress-induced THDOC and neu-
rosteroids have been demonstrated to elevate seizure threshold
(Reddy and Rogawski, 2002) and contributes to neuroprotection
(Reddy, 2003b, 2006).
11-Deoxycortisol (pregn-4-ene-17,21-diol-3,20-dione; DC) is
an immediate precursor of cortisol. DCacts as a competitive antag-
onist of glucocorticoid receptor in vitro, but is ineffective as a
glucocorticoid antagonist in vivo due to adrenal 11-hydroxylation
(Cutler et al., 1979). Nearly 50 years ago, Heuser and Eidelberg
(1961) observed that systemic administration of large doses of DC
succinate induces long-lasting seizure activity in rats and cats. The
mechanism underlying pro-epileptic properties of DC has been
studied recently (Kaminski et al., 2011). DC is capable of inducing
long-lasting status epilepticus in rodents that is refractory to sev-
eral anticonvulsant drugs. In electrophysiological studies, DC is
shown to accelerate the decay time of the inhibitory post-synaptic
currents mediated by GABA-A receptors in brain slices, indicat-
ing that it signiﬁcantly impedes GABAergic inhibition which may
lead to paroxysmal epileptiform network activity and convulsive
seizures. Because DC is an endogenous substance, it is suggested
to contribute to an increased seizure propensity in some clinical
situations. However, the speciﬁc role of DC to the pathophysiology
of epileptogenesis is remains unclear.
Physical activity has been suggested as a positive disease-
modifying factor for preventing or delaying the development of
epilepsy. Exercise has beneﬁcial effects on epileptogenesis (Arida
et al., 1998, 2007, 2010; Silva de Lacerda et al., 2007). Exercise
treatment reduced brain susceptibility in the kindling or the pilo-
carpine model of epilepsy. Behavioral analysis showed a reduced
frequency of seizures during physical exercise program. Metabolic,
electrophysiological, and immunohistochemical studies have con-
ﬁrmed the positive inﬂuence of exercise on epilepsy (Arida et al.,
1999, 2007). Although a variety of factors can contribute to such
favorable responses, the mechanisms remain poorly understood.
Dendritic plasticity, increased neurogenesis, induction of trophic
factors and release of neurosteroids are some factors underlying
the inhibitory effects of exercise on epileptogenesis. Enrichment
of environment has been shown to delay kindling epileptogen-
esis in rats (Auvergne et al., 2002). It is likely that endogenous
neurosteroids may be involved in the neuroprotective effects of
exercise and enriched environment. Thus, prevention of loss of
interneurons, reducedGABA-A receptor plasticity, and decrease in
axonal sprouting could contribute to the disease-modifying effect
of exercise and enriched environment.
Despite acute stress-induced seizure protection in animals
(Pericic´ et al., 2000; Reddy and Rogawski, 2002), patients, and
clinicians are not likely to recognize a reduction in seizure fre-
quency associated with stress. It is well known that emotional
factors can affect seizure control (Temkin and Davis, 1984). In
general, stressful events are associated with more frequent epilep-
tiform spikes and seizures (Frucht et al., 2000). Indeed, stress has
been reported to trigger seizure activity in persons with epilepsy
(Temkin and Davis, 1984; Frucht et al., 2000). During stressful
episodes adrenal hormone levels are expected to ﬂuctuate, possibly
affecting epileptogenic events. In agreement with this hypothe-
sis, perinatal stress and elevated steroid levels have been shown
accelerate epileptogenesis and lower seizure threshold in various
animal models for epilepsy (Joëls, 2009).
Acute stress has anticonvulsant-like effects, while chronic stress
is known to induce epileptic seizures. How can such contradictory
observations be reconciled? Although the exact pathophysiology
of possible seizure facilitation by stress is unknown, there are cer-
tainly many neural and endocrine pathways through which stress
can alter neuronal excitability and thereby affect seizure suscep-
tibility. The extent of seizure susceptibility during stress might
therefore represent a balance between anticonvulsant (e.g., neu-
rosteroids) and proconvulsant factors (e.g., glucocorticoids and
CRH). Stress-induced seizures would thus occur when the bal-
ance is shifted to favor the proconvulsant factors, surpassing the
anticonvulsant action of endogenous neurosteroids (Reddy,2006).
Although little is known regarding proconvulsant factors, stress
can increase brain levels of “proconvulsant” sulfated neurosteroids
such as pregnenolone sulfate (PS) and dehydroepiandrosterone
sulfate (DHEAS; see Role of Neurosteroids in Epileptogenesis).
Additionally, repeated episodes of stress and neurosteroid release
might lead to a sort of neurosteroid withdrawal-induced hyper-
excitable state (Reddy et al., 2001, 2012) and could predispose
patients to stress-induced seizures. Nevertheless, alleviating the
effects of stress by pharmacological interventions may help reduce
the epileptogenicity in people with risk factors for epilepsy.
ROLE OF NEUROSTEROIDS IN EPILEPTOGENESIS
Neurosteroids are steroids synthesized within the brain with
unconventional rapid effects on neuronal excitability. It is well
known that steroid hormones such as progesterone and DOC
can exert anticonvulsant actions (Selye, 1941; Clarke et al., 1973).
The anticonvulsant properties of progesterone and DOC are
predominantly due to their conversion in the brain to neuros-
teroids allopregnanolone (3α-hydroxy-5α-pregnane-20-one, AP)
and allotetrahydrodeoxycorticosterone (THDOC), respectively
(Reddy, 2003a; Reddy et al., 2004; Figure 2). A variety of neu-
rosteroids are known to be synthesized in the brain (Baulieu,
1981; Kulkarni and Reddy, 1995). The most widely studied
are AP, THDOC, and androstanediol. These neurosteroids are
produced via sequential A-ring reduction of the steroid hor-
mones by 5α-reductase and 3α-hydroxysteroid-oxidoreductase
(3α-HSOR) isoenzymes (Reddy, 2009a). The androgenic neu-
rosteroid androstanediol (5α-androstan-3α,17β-diol; Figure 2) is
synthesized from testosterone (Reddy, 2004a,b).
In the periphery, the steroid precursors are mainly synthesized
in the gonads, adrenal gland, and feto-placental unit, but synthesis
of these neurosteroids likely occurs in the brain from cholesterol
or from peripherally derived intermediates. Since neurosteroids
are highly lipophilic and can readily cross the blood–brain barrier,
neurosteroids synthesized in peripheral tissues accumulate in the
brain (Reddy and Rogawski, 2010). Recent evidence indicates that
neurosteroids are present mainly in principal neurons in many
brain regions that are relevant to focal epilepsies, including the
hippocampus and neocortex (Agís-Balboa et al., 2006; Saalmann
et al.,2007;DoRego et al.,2009). Thebiosynthesis of neurosteroids
is controlled by the translocator protein (18 kDa; TSPO), for-
merly called peripheral or mitochondrial benzodiazepine receptor
(Rupprecht et al., 2009, 2010). Activation of TSPO by endogenous
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signals and ligands facilitates the intramitochondrial ﬂux of
cholesterol and thereby promotes neurosteroid synthesis. It is sug-
gested that TSPO ligands might be an alternative approach for
neurosteroid therapeutics (Nothdurfter et al., 2011). Currently,
synthetic analogs of endogenous neurosteroids are under clinical
trial for treatment of epilepsy (Reddy and Rogawski, 2010, 2012).
POTENTIATION OF PHASIC AND TONIC INHIBITION
Neurosteroids rapidly alter neuronal excitability through direct
interaction with GABA-A receptors (Harrison and Simmonds,
1984; Majewska et al., 1986; Harrison et al., 1987; Gee et al.,
1988; Purdy et al., 1990; Hosie et al., 2007, 2009), which are
the major receptors for the inhibitory neurotransmitter GABA.
Activation of the GABA-A receptor by various ligands leads to an
inﬂux of chloride ions and to a hyperpolarization of the mem-
brane that dampens the excitability. Allopregnanolone and other
structurally related neurosteroids act as positive allosteric modu-
lators and direct activators of GABA-A receptors (Figure 3). At
low concentrations, neurosteroids potentiate GABA-A receptor
currents, whereas at higher concentrations, they directly acti-
vate the receptor (Harrison et al., 1987; Reddy and Rogawski,
2002). Like barbiturates, neurosteroid enhancement of GABA-A
receptors occurs through increases in both the channel open fre-
quency and channel open duration (Twyman and Macdonald,
FIGURE 3 | Neurosteroid modulation of GABA-A receptors in the brain.
Allopregnanolone and related neurosteroids binds and enhances GABA-A
receptor-mediated inhibition in the brain. GABA-A receptors are pentameric
with ﬁve protein subunits that form the chloride ion channel pore.
Neurosteroids directly binds to the “neurosteroid binding sites” and potentiate
the GABA-gated chloride currents. The neurosteroid binding sites are distinct
from sites for GABA, benzodiazepines, and barbiturates. There are two types
of GABA-A receptors with different functions. Post-synaptic GABA-A receptors,
which are pentameric chloride channels composed of 2α2βγ subunits,
mediate the phasic portion of GABAergic inhibition, while extrasynaptic
GABA-A receptors, pentamers composed of 2α2βδ subunits, primarily
contribute to tonic inhibition in the hippocampus. Neurosteroids activate both
synaptic and extrasynaptic receptors and enhance the phasic and tonic
inhibition, and thereby promote maximal network inhibition in the brain.
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1992; Lambert et al., 2009; Ramakrishnan and Hess, 2010). The
GABA-A receptor is a pentamer consisting of ﬁve subunits that
form a chloride channel. Sixteen subunits (α1-6, β1-3, γ1-3, δ, ε,
θ, and π subunits) have been identiﬁed so far. The GABA site is
located at the interface between α and β subunits. Benzodiazepines
bind at the interface between α and γ subunits and they interact
with subunit combinations α1,2,3,5β2γ2.
Activation of GABA-A receptors produces two forms of inhibi-
tion: phasic inhibition generated by the rapid, transient activation
of synaptic GABA-A receptors by presynaptic GABA release, and
tonic inhibition generated by the persistent activation of extrasy-
naptic GABA-A receptors, which can detect extracellular GABA
(Figure 3). There are major differences between synaptic and
extrasynaptic GABA-A receptors (Table 3). The extrasynaptic
GABA-A receptors are distributed within the hippocampus (α4βδ,
α5βδ, orα1βδ), neocortex (α4βδ,α5βδ), thalamus (α4βδ), striatum
(α4βδ), hypothalamus (α4βδ), and cerebellum (α6βδ). Although
GABA activates synaptic (γ2-containing) GABA-A receptors with
high-efﬁcacy,GABA activation of the extrasynaptic (δ-containing)
GABA-A receptors are limited to low-efﬁcacy activity character-
ized by minimal desensitization and brief openings. Such tonic
currents are particularly evident in dentate granule cells, which
play a major role in hippocampus excitability. The high sensitiv-
ity of δ-containing receptor channels to neurosteroid modulation
may be dependent on the δ-subunit or the low-efﬁcacy chan-
nel function that it confers. There is evidence that neurosteroids
preferentially enhance low-efﬁcacy GABA-A receptor activity
independent of subunit composition (Bianchi and Macdonald,
2003).
The effect of neurosteroids on GABA-A receptors occurs by
binding to discrete sites on the receptor–channel complex that
are located within the transmembrane domains of the α- and
β-subunits (Hosie et al., 2006, 2007), which they access by lat-
eral membrane diffusion (Chisari et al., 2009, 2010; Figure 3).
The binding sites for neurosteroids are distinct from the recog-
nition sites for GABA, benzodiazepines, and barbiturates (Hosie
et al., 2009). Androgenic neurosteroids such as androstanediolmay
interact with these sites, and a recent study indicates that this agent
is a positive allosteric modulator of GABA-A receptors (Reddy and
Jian, 2010). Although neurosteroids act on all GABA-A-receptor
isoforms, they have large effects on extrasynaptic δ-subunit con-
taining GABA-A receptors that mediate tonic currents (Belelli
et al., 2002; Wohlfarth et al., 2002). The potentiation of δ-
subunit-containing receptors by THDOC and other neurosteroids
is selective for channels with low-efﬁcacy gating characteristics
marked by brief bursts and channel openings in conditions of
both low and high GABA concentrations, and neurosteroids can
thereby preferentially increase the efﬁcacy of these receptors based
on pharmacokinetics which are not yet fully understood (Bianchi
andMacdonald, 2003). Neurosteroids thereforemarkedly enhance
the current generated by δ-subunit-containing receptors even in
the presence of saturating GABA concentrations. Consequently,
GABA-A receptors that contain the δ-subunit are highly sensitive
to neurosteroid potentiation and mice lacking δ-subunits show
drastically reduced sensitivity to neurosteroids (Mihalek et al.,
1999; Spigelman et al., 2002). Tonic current causes a steady inhi-
bition of neurons and reduces their excitability. Neurosteroids
therefore could play a role in setting the level of excitability by
potentiation of tonic inhibition during seizures when ambient
GABA rises (Stell et al., 2003).
The pharmacological proﬁle of major neurosteroids is outlined
in Table 4. Allopregnanolone-like neurosteroids are powerful anti-
seizure agents. Exogenously administered neurosteroids exhibit
broad-spectrum anticonvulsant effects in diverse rodent seizure
models (Reddy, 2010). Neurosteroids protect against seizures
induced by GABA-A receptor antagonists, including pentylenete-
trazol and bicuculline, and are effective against pilocarpine-
induced limbic seizures and seizures in kindled animals (Belelli
et al., 1989; Kokate et al., 1994; Frye, 1995; Wieland et al., 1995;
Reddy and Rogawski, 2001, 2010; Kaminski et al., 2004, 2005;
Reddy et al., 2004). Like other GABAergic agents, they may exac-
erbate generalized absence seizures (Snead, 1998; Citraro et al.,
2006). The potencies of neurosteroids inmodels where they confer
seizure protection vary largely in accordance with their activities
as positive allosteric modulators of GABA-A receptors (Reddy,
2004a,b; Kaminski et al., 2005). Like other GABAergic agents,
Table 3 | An overview of synaptic (αβγ2-containing) and extrasynaptic (αβδ-containing) GABA-A receptors in the brain.
Synaptic GABA-A receptors Extrasynaptic GABA-A receptors
Pentameric chloride ion channels Pentameric chloride ion channels
Contributes to phasic inhibition Contributes to tonic inhibitiion
Low GABA afﬁnity High GABA afﬁnity
High GABA efﬁcacy Low GABA efﬁcacy
Pronounced desensitization Moderate or low desensitization
Mainly synaptic localization Perisynaptic and extrasynaptic sites
Benzodiazepine sensitive Benzodiazepine insensitive
Potentiated by neurosteroids Highly potentiated by neurosteroids
Not blocked by low [Zn2+] Blocked by low [Zn2+]
Distributed widely within the brain: cortex, hippocampus, amygdala,
limbic structures, thalamus, hypothalamus, cerebellum
Selective distribution in few brain regions: hippocampus, neocortex,
thalamus, hypothalamus, cerebellum
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Table 4 | Pharmacological profile of major neurosteroids in animal
models.
Seizure model Allopreg- THDOC Andro-
nanolone stanediol
Kindling models
Hippocampus kindling 3.5 ND 50 (36-64)
Amygdala kindling 14 (8–23) 15 (10–30) ND
Chemoconvulsant models
Pentylenetetrazol 12 (10–15) 19 (77–122) 40 (27–60)
Bicuculline 12 (10–15) 12 (10–15) 44 (24–81)
Picrotoxin 10 (5–19) 10 (5–19) 39 (21–74)
N -Methyl-D-aspartate >40 >40 >200
Kainic acid >40 >40 >200
4-Aminopyridine >40 >40 >200
Electroshock models
Maximal electroshock 29 (19–44) 48 (35–66) ND
6-Hz stimulation 14 (10–19) ND ND
Status epilepticus models
Pilocarpine 7 (4–13) 7 (4–13) 81 (45–133)
The proﬁle of neurosteroids is expressed in terms of ED50, which is the dose in
mg/kg producing seizure protection in 50% of animals. Values in parentheses are
95% conﬁdence limits. ND, not determined.
neurosteroids are inactive or only weakly active against seizures
elicited by maximal electroshock. Neurosteroids are highly active
in the 6-Hz model, a better paradigm in which limbic-like seizures
are induced by electrical stimulation of lower frequency and longer
duration than in the maximal electroshock test (Kaminski et al.,
2004). Androstanediol, but not its 3β-epimer, produced a dose-
dependent suppression of behavioral and electrographic seizures
in the mouse hippocampus kindling (Reddy and Jian, 2010). In
addition, neurosteroids are also highly effective in suppressing
seizures due to withdrawal of GABA-A receptor modulators
including neurosteroids and benzodiazepines, as well as other
types of agents such as ethanol and cocaine (Devaud et al., 1996;
Tsuda et al., 1997; Reddy and Rogawski, 2001; Gangisetty and
Reddy, 2010). In contrast to benzodiazepines, where utility in
the chronic treatment of epilepsy is limited by tolerance, anti-
convulsant tolerance is not evident with neurosteroids (Kokate
et al., 1998; Reddy and Rogawski, 2000), which indicate that neu-
rosteroids are more effective than benzodiazepines for long-term
treatment. Novel therapeutic approaches are being developed
based on the emerging information on neurosteroid interaction
with GABA-A receptors (Reddy and Rogawski, 2009; Murashima
and Yoshii, 2010).
ANTIEPILEPTOGENIC ACTIVITY
Neurosteroids may play a role in chronic epilepsy. Neurosteroid
modulation of tonic activation of extrasynaptic GABA-A recep-
tors can regulate excitability during epileptogenicity. Given the
complex plasticity in GABA-A receptors in epilepsy, it is difﬁcult
to predict the functional outcomeof altered subunit compositions.
A consistent ﬁnding from studies that have used various models of
chronic epilepsy is that tonic conductances are largely preserved
in epileptic brain around the time when synaptic inhibition is
reduced (Mtchedlishvili et al., 2001; Sun et al., 2007; Zhang et al.,
2007). Studies in a status epilepticus model of TLE have shown a
striking reduction in δ-subunit containing GABA-A receptors in
the dentate gyrus (Peng et al., 2004; Zhang et al., 2007), suggesting
that neurosteroid effects on non-synaptic GABA-A receptors may
be reduced. There was a compensatory increase in γ2-subunit, so
that tonic inhibition is preserved though the efﬁcacy of THDOC in
modulating tonic current is decreased. In addition, neurosteroid
modulation of synaptic currents is diminished in dentate gyrus
granule cells and α4-subunit-containing receptors are expressed
at synaptic sites (Sun et al., 2007). All of these changes may
exacerbate seizures in epileptic animals and reduce the potency
but not efﬁcacy of endogenous neurosteroids. The expression
of neurosteroidogenic enzymes such as P450scc and 3α-HSOR
appears to be elevated in the hippocampus in animals and human
subjects affected by TLE (Stoffel-Wagner et al., 2000; VMDB
Report, 2003; Biagini et al., 2009). If local neurosteroidogenesis is
enhanced, this may in part counteract the epileptogenesis-induced
changes.
There is emerging evidence that endogenous neurosteroids play
a role in regulating epileptogenesis (Edwards et al., 2001; Biagini
et al., 2006, 2009, 2010; Reddy et al., 2010; Figure 4). Using the
kindling model, we demonstrated that the development and per-
sistence of limbic epileptogenesis are impaired in mice lacking
PRs (Reddy and Mohan, 2011). To explore mechanisms under-
lying the observed seizure resistance, we investigated the role
of neurosteroids using ﬁnasteride, a 5α-reductase inhibitor that
blocks the synthesis of progesterone-derived neurosteroids. We
determined the rate of rapid kindling in both control animals
and those which had received injections of progesterone with
or without concurrent ﬁnasteride treatment (Reddy and Mohan,
2011). Progesterone produced a signiﬁcant delay in the rate of
kindling and pretreatment with ﬁnasteride blocked progesterone’s
inhibition of kindling epileptogenesis (Reddy and Ramanathan,
2012). These ﬁndings are consistent with a contributory role of
neurosteroids in limbic epileptogenesis. Thus, it is possible that
inhibition of neurosteroids could incite mechanisms that may
promote epileptogenesis.
The P450sc is a critical enzyme for the biosynthesis of neu-
rosteroids (Figure 2). It is present in neurons, oligodendro-
cytes, astrocytes, and activated microglia. Following pilocarpine-
induced status epilepticus in the rat, the neurosteroidogenic
enzyme P450scc is upregulated for several weeks, suggesting that
it may be associated with promotion of neurosteroidogenesis
(Biagini et al., 2009). Ordinarily, rats develop spontaneous recur-
rent seizures following a latent period of similar duration to the
period during which P450scc is elevated. The role of neurosteroids
in delaying seizure onset in the pilocarpine model is conﬁrmed
using ﬁnasteride, which can exacerbate seizures by inhibition
of neurosteroid synthesis. Inhibiting neurosteroid synthesis with
ﬁnasteride accelerated the onset of spontaneous recurrent seizures
(Biagini et al., 2006), suggesting that endogenous neurosteroids
play a role in restraining epileptogenesis, or at least act to inhibit
the expression of seizures.
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FIGURE 4 | Potential molecular mechanisms of neurosteroid
interruption of epileptogenesis. In the brain, allopregnanolone and
related neurosteroids may retard epileptogenesis by the interruption of
one or more of the pathways leading to development of epilepsy, which
generally occurs following an initial precipitating event. Neurosteroids
such as allopregnanolone binds to synaptic and extrasynaptic GABA-A
receptors and enhances phasic and tonic inhibition within the brain,
and thereby may affect epileptogenesis. Other potential mechanisms
include modulation of neuroinﬂammation and neurogenesis in the
brain.
The development of epilepsy is linked to complex alterations
in neuroplastic mechanisms. Dysregulation of neurosteroid syn-
thesis may also play a role. This premise is being tested in various
epileptogenic models (Reddy and Mohan, 2011). We investigated
the role of the prototype endogenous neurosteroid allopreg-
nanolone in controlling limbic epileptogenesis. Treatment with
ﬁnasteride, a neurosteroid synthesis inhibitor, resulted in a sig-
niﬁcant increase in epileptogenesis in the hippocampus kindling
model (Ramanathan and Reddy, 2011). Exogenous administra-
tion of allopregnanolone, at doses that produce levels similar
to gonadotropins, markedly inhibited epileptogenesis. In female
epilepsy rats, ﬁnasteride treatment exacerbates seizure frequency
(Lawrence et al., 2010). Neurosteroid-mediated increase in tonic
inhibition in the hippocampus could inhibit the spread of the
seizure discharge from the hippocampal focus and thereby sup-
press the rate of development of behavioral kindled seizure
activity without affecting the focal electrographic discharges
(Figure 4). The exact mechanisms are unclear. Increased tonic
inhibition by allopregnanolone is shown to impair the NMDA
(N-methyl-D-aspartate) receptor-mediated excitability in the
hippocampus (Shen et al., 2010). It is likely that such a mechanism
may underlie the progesterone’s disease-modifying effects in the
kindling model. Based on these pilot studies, it is suggested that
augmentation of neurosteroid synthesis may represent a unique
strategy for preventing or retarding epileptogenesis.
PROCONVULSANT AND EPILEPTOGENIC ACTIVITY
Neurosteroids that are sulfated at C3 have inhibitory actions on
GABA-A receptors (Park-Chung et al., 1999). PS and DHEAS
block GABA-A receptors at low micromolar concentrations
(Majewska,1992). These“sulfated steroids”act as non-competitive
antagonists of the GABA-A receptor by interacting with a site that
is distinct from that of neurosteroids such as allopregnanolone
and THDOC (Majewska and Schwartz, 1987; Majewska et al.,
1990; Park-Chung et al., 1999). The steroid negative modula-
tory action on GABA-A receptors occurs through a reduction
in channel opening frequency, although the precise mecha-
nism of block is not well understood (Mienville and Vicini,
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1989; Akk et al., 2001). PS has been shown to possess agonis-
tic actions on NMDA receptors (Wu et al., 1991) and presynaptic
sites (Mtchedlishvili and Kapur, 2003). Given their abundance in
brain, it seems reasonable that PS and DHEAS could function as
endogenous neuromodulators. In contrast to allopregnanolone,
sulfated neurosteroids PS and DHEAS exert proconvulsant or
convulsant actions (Reddy and Kulkarni, 1998; Kokate et al.,
1999b). Direct injection of PS to rodent brain elicits seizures
which increase in severity and frequency with time and even-
tually progress to status epilepticus, tonic hindlimb extension,
and death of the animals (Kokate et al., 1999b; Williamson et al.,
2004). However, systemic administration of PS does not induce
overt seizure activity (Kokate et al., 1999b). The pharmacol-
ogy of PS seizures is poorly understood, but both clonazepam
and allopregnanolone can effectively protect against PS-induced
seizure activity (Kokate et al., 1999b). The proconvulsant effect
of DHEAS is reduced by progesterone, an intermediate precur-
sor of neurosteroid synthesis. Moreover, exogenous application
or endogenous stimulation of DHEAS modulates hippocampal
GABA inhibition possibly by entraining hippocampal neurons
to theta rhythm (Steffensen, 1995), suggesting a potential phys-
iological relevance of the proconvulsant effects of DHEAS in
animals.
GENDER DIFFERENCES IN EPILEPSY AND NEUROSTEROIDS
Epilepsy shows sex differences in incidence, progression, and
severity, as well as in responsiveness to therapy. The incidence
of epilepsy is generally higher in males than in females. More
women than men are diagnosed with idiopathic generalized
epilepsy, but localization-related symptomatic epilepsies are more
frequent in men, and cryptogenic localization-related epilepsies
are more frequent in women (Hauser, 1997; Christensen et al.,
2005). Sex differences have been described in patients with TLE,
with respect to distinct regional distribution of brain dysfunc-
tion during interictal periods as well as to the extent of neuronal
damage. Women tend to have less structural atrophy than men,
regardless of the seizure rate. During brain development, sex
hormones have organizational effects leading to permanent dif-
ferences between males and females in distinct brain regions
(Velíšková, 2009). However, the precise mechanisms underlying
the sex-dependent differentiation of the speciﬁc neuronal cir-
cuits, particularly brain regions involved in seizure control, are
not clear. Many factors are involved in determining sex differ-
ences in seizure susceptibility, including the presence of sexual
dimorphism in brain structures involved in seizure generation
and control, in regional connectivity, sensitivity of neurotransmit-
ter systems, receptor distribution, and dependence on hormonal
milieu and on changes in sex hormone levels during the life
span.
Neurosteroids exhibit a strong gender differences in their phar-
macological effects with more potency in females than males
(Reddy, 2009b). Steroid hormones such as progesterone and
testosterone play a key role in the gender-related differences in
susceptibility to seizures. However, the precise mechanism under-
lying such sexual dimorphism is obscure. Many of the biological
actions of steroid hormones are mediated through intracellular
receptors. Studies have suggested that these sex differences in
seizure sensitivity are due to gender-speciﬁc distribution of steroid
hormones or other sexually dimorphic characteristics in speciﬁc
brain areas relevant to epilepsy. For example, estradiol reduces
seizure-induced hippocampal injury in ovariectomized female but
not in male rats, suggesting that the effects of estradiol on seizure
threshold and damage may be determined by sex-related differ-
ences in the hormonal environment. Neurosteroids may play a key
role in gender-related differences in seizure susceptibility (Reddy,
2009b). Both progesterone and allopregnanolone protect against
experimental seizures in both male and female mice lacking PRs
(Reddy et al., 2004). However, female mice exhibit signiﬁcantly
enhanced sensitivity to the protective activity of allopregnanolone
as compared to males. In the pilocarpine seizure test, androstane-
diol has similar increased potency in female mice, which is not
related to differences in pharmacokinetics of this neurosteroid.
These results underscore the possible role of endogenous neuros-
teroids in gender-related differences in seizure susceptibility and
protection.
POTENTIAL SIDE EFFECTS OF NEUROSTEROIDS
Steroid hormones such as progesterone and DOC have long
been known to have sedative, anesthetic, and antiseizure prop-
erties (Aird, 1944; Gyermek et al., 1967; Green et al., 1978).
Studies during the past three decades have uncovered that neu-
rosteroids mediate such rapid effects of steroid hormones in
the brain (Reddy et al., 2004, 2005). Unlike steroid hormones,
the acute effects of neurosteroids are not related to interactions
with classical steroid hormone receptors that regulate gene tran-
scription. Moreover, neurosteroids are not themselves active at
intracellular steroid receptors. They modulate brain excitabil-
ity primarily by interaction with neuronal membrane receptors
and ion channels, principally GABA-A receptors. Therefore, like
other GABAergic agents, neurosteroids have sedative and anx-
iolytic properties (Reddy, 2003a). At high doses, neurosteroids
cause anesthetic effects. This feature is exempliﬁed with alphax-
olone, which was introduced as intravenous anesthetic in 1970s.
It was withdrawn later from the market due to toxicity of the sol-
vent used for formulation of this synthetic neurosteroid. Although
natural neurosteroids can be used for therapeutic purpose in
patients with epilepsy, certain obstacles prevent the clinical use
of endogenous neurosteroids. First, natural neurosteroids such as
allopregnanolone have low bioavailability because they are rapidly
inactivated and eliminated by glucuronide or sulfate conjugation
at the 3α-hydroxyl group. Secondly, the 3α-hydroxyl group of
allopregnanolone may undergo oxidation to the ketone, restoring
activity at steroid hormone receptors (Rupprecht et al., 1993). Syn-
thetic neurosteroids, which are devoid of such hormonal actions,
could provide a rational alternative approach to therapy (Reddy
and Kulkarni, 2000). Recently, a number of synthetic analogs
of allopregnanolone and other neurosteroids are tested in ani-
mals and human trials. Ganaxolone, the 3β-methyl analog of
allopregnanolone, is a synthetic neurosteroid analog that over-
comes these limitations (Carter et al., 1997). Results from the
clinical trials of ganaxolone demonstrated a benign side effect
proﬁle (Reddy and Woodward, 2004). More than 900 subjects
(adults and children) have received this neurosteroid in Phase
1 and 2 trials. Overall, the drug is safe and well tolerated. The
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Table 5 | Pipeline of new drugs for epilepsy under development.
Agent Pharmacological profile
BGG492 (Novartis) A competitive AMPA/kainate receptor antagonist
Brivaracetam (UCB) A novel high-afﬁnity synaptic vesicle protein 2A (SV2A) ligand
CPP-115 (Catalyst) A GABA transaminase inhibitor (vigabatrin derivative)
ICA-105665 (Pﬁzer) A highly selective opener of neuronal Kv7 (KCNQ) potassium channels
T2000 (Taro) A non-sedating barbiturate (prodrug of diphenylbarbituric acid)
Tonabersat (Upsher-Smith) A novel mechanism of uncoupling of neuronal gap junctions
UCB-0942 (UCB) A new pre-and post-synaptic inhibitor
VX765 (Vertex) A selective inhibitor of interleukin converting enzyme
YKP3089 (SK Life) Novel mechanism of action
2-Deoxy-D-glucose (NeuroGenomeX) A glucose analog and glycolytic inhibitor
Ganaxolone (Marinus) A synthetic neurosteroid and GABA-A receptor modulator
Imepitoin (BI) A low-afﬁnity partial agonist at the benzodiazepine site of the GABA-A receptor
NAX 810-2 (NeuroAdjuvants) Galanin receptor GalR1 and GalR2 agonist
Valnoctamide (Hebrew Univ) Valproic acid second generation derivative
most common side effect is reversible dose-related sedation. Other
adverse events reported by few subjects include dizziness, fatigue,
and somnolence, which indicate its GABAergic effects.
CONCLUSION
The major part of the pathophysiology of epilepsy is epilepto-
genesis, whereby a normal brain becomes progressively epileptic
because of injury factors. Despite increased scientiﬁc awareness,
there is a large gap in our understanding of epileptogenesis and
many questions remain unanswered regarding the cellular and
molecular mechanisms underlying the “irreversible conversion”
of a normal brain into epileptic brain predisposed to recurrent
seizures. Such gaps in our knowledge about epilepsy’s risk factors,
comorbidities, and outcomes limit the ability of clinical programs
toprevent epilepsy and its consequences. Since theCuringEpilepsy
conference in 2000, there has been more focused research on opti-
mizing approaches in preventing epilepsy and there is emphasis
on several translation models. Reduction in neuroinﬂammation
and neurodegeneration is a widely targeted approach for curing
epilepsy. Despite intense search for drugs that interrupt epilep-
togenesis, presently there is no FDA-approved drug available for
prevention of epilepsy development in patients at risk. It is essen-
tial to ﬁnd a lead target, such as a receptor or signaling pathway
that is crucial for the progression of epileptogenesis that can be
disrupted by pharmacological agents to prevent or retard epilepsy.
A variety of pharmacological agents have been tested in ani-
mal models of epileptogenesis and in clinical trials in patients
with a risk factor for epilepsy. However, the outcomes are not
highly promising. The pipeline of new drugs for clinical devel-
opment is very limited. A summary of agents that are currently
in development for epilepsy is listed in Table 5. Steroid hor-
mones, especially corticosteroids, estrogen, and progesterone play
an important role in epilepsy. Repetitive stress and corticosteroids
increases the risk of epilepsy. There is emerging evidence that neu-
rosteroids may play a role in limbic epileptogenesis. Neurosteroids
that enhance the GABAergic inhibition within the brain are potent
anticonvulsants and they regulate neural excitability networks by
enhancing the phasic and tonic inhibition in the hippocampus, a
critical region involved in the TLE. Tonic inhibition is therefore
an attractive target for antiepileptogenic drugs (Figure 4). The
effects of stress and hormonal changes on neuronal excitability
are most likely mediated by neurosteroids. Therefore, menstrual,
gonadal, and stress-related ﬂuctuations in neurosteroids or dys-
function in their synthesis can alter epileptogenesis in people at
risk for epilepsy. As pleotropic agents, steroid hormones can mod-
ify, interrupt or reverse the epileptogenic process, such as cell
loss, neuroinﬂammation, neurogenesis, astrogliosis, and axonal
sprouting.
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